AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20338954 — intervention group
Group type: COMPARATOR
Intervention: No analgesia
Number of subjects: 64
Study 17328965 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta‐1a 30 microg intramuscularly (IM) once‐weekly (qw) (n=8)
Number of subjects: 15
Study 17328965 — intervention group
Group type: COMPARATOR
Intervention: IFN‐beta‐1a 44 microg subcutaneously (SC) three‐times‐weekly (tiw) (n=7)
Number of subjects: 15
Study 16353395 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone (10 mg in 2 ml)
Number of subjects: 162
Study 16353395 — intervention group
Group type: COMPARATOR
Intervention: i.v. placebo (2 ml of normal saline)
Number of subjects: 162
Study 11432685 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise (3-4 miles jogging 3 times per week) for 10 weeks
Number of subjects: 12
Study 11432685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11432685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone (0.3 mg/kg)
Number of subjects: 12
Study 11432685 — intervention group
Group type: EXPERIMENTAL
Intervention: m-CPP (0.4 mg/kg)
Number of subjects: 12
Study 11432685 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral response to ipsapirone
Number of subjects: 12
Study 11432685 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean maximal increases of plasma adrenaline and noradrenaline
Number of subjects: 12
Study 9752300 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (M) therapy
Number of subjects: 129
Study 9752300 — intervention group
Group type: COMPARATOR
Intervention: No Morphine (M-)
Number of subjects: 129
Study 8151855 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot humidified air (42-44 degrees C)
Number of subjects: 20
Study 8151855 — intervention group
Group type: COMPARATOR
Intervention: Room temperature air (22 degrees C)
Number of subjects: 20
Study 8151855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 3246253 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (6 mg i.v.)
Number of subjects: 17
Study 3246253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31291976 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at 'Wang's Jiaji' acupoints, five times a week for 2 weeks.
Number of subjects: 100
Study 31291976 — intervention group
Group type: COMPARATOR
Intervention: 10mg baclofen three times a day for 2 weeks.
Number of subjects: 100
Study 28365959 — intervention group
Group type: COMPARATOR
Intervention: PPPD with standard lymphadenectomy (N1=30)
Number of subjects: 60
Study 28365959 — intervention group
Group type: EXPERIMENTAL
Intervention: PPPD with extended lymphadenectomy (N2=30)
Number of subjects: 60
Study 28365959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression analysis
Number of subjects: 60
Study 26242858 — intervention group
Group type: EXPERIMENTAL
Intervention: Publication of British Society for Rheumatology guidelines in 2006
Number of subjects: 11772
Study 26242858 — intervention group
Group type: COMPARATOR
Intervention: Pre-guidelines prescribing trend
Number of subjects: 11772
Study 26242858 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-guidelines prescribing trend
Number of subjects: 11772
Study 23282123 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 0
Study 23282123 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 40 mg
Number of subjects: 0
Study 21481442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide (30 mg subcutaneous)
Number of subjects: 0
Study 21481442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19690559 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin continued after switching to insulin
Number of subjects: 0
Study 19690559 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy
Number of subjects: 0
Study 17054883 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-specific analysis methods using a three-segment model for gait analysis
Number of subjects: 20
Study 12751337 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak aerobic exercise (5 minutes at 90%)
Number of subjects: 8
Study 12751337 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged submaximal exercise (2 hours at 60%)
Number of subjects: 8
Study 12751337 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (3 sets of 10 repetitions at 60 to 70% of 1-RM)
Number of subjects: 8
Study 12751337 — intervention group
Group type: COMPARATOR
Intervention: Seated control (5 hours)
Number of subjects: 8
Study 11093927 — intervention group
Group type: EXPERIMENTAL
Intervention: DIU (diuretic administration; Novotriamazide; 100 mg triamterene and 50 mg hydrochlorothiazide)
Number of subjects: 10
Study 11093927 — intervention group
Group type: EXPERIMENTAL
Intervention: DIU
Number of subjects: 10
Study 11093927 — intervention group
Group type: COMPARATOR
Intervention: CON (placebo)
Number of subjects: 10
Study 11093927 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 10
Study 9028776 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 12
Study 9028776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Japanese sentences (speech)
Number of subjects: 12
Study 9028776 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese sentences played backward (reversed speech)
Number of subjects: 12
Study 9028776 — intervention group
Group type: COMPARATOR
Intervention: Silence
Number of subjects: 12
Study 8174724 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) 2 mg SC
Number of subjects: 21
Study 8174724 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG 10,000 IU IM
Number of subjects: 21
Study 8174724 — intervention group
Group type: COMPARATOR
Intervention: Both LA and hCG
Number of subjects: 21
Study 3371847 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (a‐IFN) treatment at a standard i.m. dose of 0.7‐1.0 X 10(5)/kg/day for 28 consecutive days, followed by the same dose twice a week for two months.
Number of subjects: 28
Study 3371847 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 28
Study 29582896 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefrailty (defined as exhibiting one or two of the five Fried criteria)
Number of subjects: 447
Study 29582896 — intervention group
Group type: EXPERIMENTAL
Intervention: Components of the Fried criteria (slow gait speed and loss of activity)
Number of subjects: 447
Study 29582896 — intervention group
Group type: COMPARATOR
Intervention: Robust individuals (control group)
Number of subjects: 447
Study 27550552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered by nonclinician sleep coaches
Number of subjects: 159
Study 27550552 — intervention group
Group type: COMPARATOR
Intervention: General sleep education (Control)
Number of subjects: 159
Study 25686383 — intervention group
Group type: EXPERIMENTAL
Intervention: New leaflet
Number of subjects: 792
Study 25686383 — intervention group
Group type: COMPARATOR
Intervention: Old leaflet
Number of subjects: 792
Study 25686383 — intervention group
Group type: EXPERIMENTAL
Intervention: Both leaflets
Number of subjects: 792
Study 24429245 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-care worker instruction
Number of subjects: 481
Study 24429245 — intervention group
Group type: COMPARATOR
Intervention: Induction
Number of subjects: 481
Study 19347247 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 g of protein supplement (SUP) ingested pre- and post-exercise
Number of subjects: 15
Study 19347247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study 19347247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SUP and PL)
Number of subjects: 15
Study 17522599 — intervention group
Group type: EXPERIMENTAL
Intervention: rye bread with sunflower seeds (SU)
Number of subjects: 11
Study 17522599 — intervention group
Group type: EXPERIMENTAL
Intervention: rye bread with flaxseeds (FL)
Number of subjects: 11
Study 17522599 — intervention group
Group type: COMPARATOR
Intervention: rye bread
Number of subjects: 11
Study 17522599 — intervention group
Group type: EXPERIMENTAL
Intervention: low extraction rate rye bread with SU and FL
Number of subjects: 11
Study 16680464 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasonography measuring angle-corrected time-averaged flow velocity and cross-sectional area of common hepatic artery and portal vein in women with severe preeclampsia
Number of subjects: 58
Study 16680464 — intervention group
Group type: COMPARATOR
Intervention: Doppler ultrasonography measuring angle-corrected time-averaged flow velocity and cross-sectional area of common hepatic artery and portal vein in healthy pregnant controls
Number of subjects: 58
Study 11948038 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp protocol
Number of subjects: 22
Study 11948038 — intervention group
Group type: COMPARATOR
Intervention: 1-min step protocol
Number of subjects: 22
Study 9771302 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil with isoflurane (Group I, n = 115)
Number of subjects: 251
Study 9771302 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group P, n = 118)
Number of subjects: 251
Study 7622080 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (1000 mg i.m. daily for 15 days)
Number of subjects: 50
Study 7622080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1978467 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (mean daily dose 353 mg)
Number of subjects: 72
Study 1978467 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (mean daily dose 11 mg)
Number of subjects: 72
Study 609193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (200 mg i.m. weekly)
Number of subjects: 37
Study 609193 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 37
Study 6279347 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TCS) applied over the site of pain
Number of subjects: 700
Study 6279347 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TCS) applied over major nerve trunks proximally
Number of subjects: 700
Study 6279347 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TCS)
Number of subjects: 700
Study 6279347 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted electrodes for prolonged stimulation of damaged peripheral nerves
Number of subjects: 700
Study 30740767 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for New Mums smartphone application for 6 weeks post birth
Number of subjects: 0
Study 30740767 — intervention group
Group type: COMPARATOR
Intervention: Standardized institutional postnatal care services
Number of subjects: 0
Study 29185134 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT before + PBMT after
Number of subjects: 77
Study 29185134 — intervention group
Group type: COMPARATOR
Intervention: Placebo before + placebo after
Number of subjects: 77
Study 27090485 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of progressive high-load power training, 2 sessions per week
Number of subjects: 37
Study 27090485 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 37
Study 24476226 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 25
Study 24476226 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 24476226 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel warming
Number of subjects: 25
Study 22480275 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression-study group (n = 16)
Number of subjects: 30
Study 22480275 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural-study group (n = 14)
Number of subjects: 30
Study 22480275 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (combined results)
Number of subjects: 30
Study 18616837 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Food Photography Method (RFPM)
Number of subjects: 52
Study 17430382 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-assisted vein sclerotherapy (KAVS) using foamed polidocanol
Number of subjects: 30
Study 16354469 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin plus 600 mg of rifampicin (OR, n = 41)
Number of subjects: 118
Study 16354469 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of doxycycline plus 600 mg of rifampicin (DR, n = 45)
Number of subjects: 118
Study 16354469 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g intramuscularly streptomycin plus 200 mg doxycycline (DS, n = 32)
Number of subjects: 118
Study 12194667 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-activated bonding material
Number of subjects: 25
Study 12194667 — intervention group
Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 25
Study 9855438 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination vaccine
Number of subjects: 0
Study 9855438 — intervention group
Group type: COMPARATOR
Intervention: Separately administered components
Number of subjects: 0
Study 7715294 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir 25 mg three times daily
Number of subjects: 49
Study 7715294 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir 75 mg three times daily
Number of subjects: 49
Study 7715294 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir 200 mg three times daily
Number of subjects: 49
Study 7715294 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir 600 mg three times daily
Number of subjects: 49
Study 2655818 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofragmentable anastomosis ring (BAR)
Number of subjects: 202
Study 2655818 — intervention group
Group type: COMPARATOR
Intervention: Sutured anastomosis
Number of subjects: 202
Study 2655818 — intervention group
Group type: COMPARATOR
Intervention: Stapled anastomosis
Number of subjects: 202
Study 1013853 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine douche and gel
Number of subjects: 0
Study 1013853 — intervention group
Group type: COMPARATOR
Intervention: Other methods of vaginal preparation
Number of subjects: 0
Study 30394805 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon® for 1 month
Number of subjects: 450
Study 30394805 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon® for 3 months
Number of subjects: 450
Study 29493163 — intervention group
Group type: EXPERIMENTAL
Intervention: ACPV decoction (treatment group)
Number of subjects: 60
Study 29493163 — intervention group
Group type: COMPARATOR
Intervention: Deanxit (control group)
Number of subjects: 60
Study 25409167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac (90 mg)
Number of subjects: 343
Study 25409167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 23328126 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3-Acid Ethyl Esters (4 g/day)
Number of subjects: 0
Study 23328126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21806837 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic Yin and Yang Tonic Granule
Number of subjects: 0
Study 21806837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19836709 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft combined with Fisiograft
Number of subjects: 16
Study 19836709 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone graft alone
Number of subjects: 16
Study 17086021 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg/d
Number of subjects: 63
Study 17086021 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg/d
Number of subjects: 63
Study 17086021 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/d
Number of subjects: 63
Study 17086021 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/d + Quinapril 20 mg/d
Number of subjects: 63
Study 17086021 — intervention group
Group type: COMPARATOR
Intervention: Healthy normotensive subjects (normal)
Number of subjects: 63
Study 15577824 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization to food or aeroallergens
Number of subjects: 285
Study 15577824 — intervention group
Group type: EXPERIMENTAL
Intervention: Aeroallergen sensitization
Number of subjects: 285
Study 15577824 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood eosinophil level of 4% or greater
Number of subjects: 285
Study 15577824 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum IgE level greater than 100 IU/mL
Number of subjects: 285
Study 15577824 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilia and total serum IgE level correlation with aeroallergen sensitization
Number of subjects: 285
Study 12033350 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 109
Study 12033350 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy or ICD
Number of subjects: 109
Study 12033350 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible patients with ICD
Number of subjects: 109
Study 12033350 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 109
Study 9661649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol-producing adenoma
Number of subjects: 19
Study 9661649 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen-secreting adrenocortical carcinoma
Number of subjects: 19
Study 9661649 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone-producing adenoma
Number of subjects: 19
Study 9661649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfunctional adenomas
Number of subjects: 19
Study 9661649 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone-producing adenomas
Number of subjects: 19
Study 9661649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol-producing adenomas
Number of subjects: 19
Study 9661649 — intervention group
Group type: COMPARATOR
Intervention: Normal adrenals
Number of subjects: 19
Study 9661649 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenocortical tumors
Number of subjects: 19
Study 7662596 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol treatment
Number of subjects: 25
Study 2694006 — intervention group
Group type: EXPERIMENTAL
Intervention: Calciheparin
Number of subjects: 20
Study 2694006 — intervention group
Group type: COMPARATOR
Intervention: Defibrotide
Number of subjects: 20
Study 361799 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine associated with cyclophosphamide and 5-fluoro-uracil
Number of subjects: 603
Study 361799 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicine
Number of subjects: 603
Study 361799 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 603
Study 31002317 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally interrupted dabigatran therapy
Number of subjects: 442
Study 31002317 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted warfarin therapy
Number of subjects: 442
Study 28599894 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 444
Study 28599894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 444
Study 26635204 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-inducing specially processed cereals (SPC)
Number of subjects: 32
Study 26635204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control cereal)
Number of subjects: 32
Study 24048776 — intervention group
Group type: EXPERIMENTAL
Intervention: Symphytum herb extract cream
Number of subjects: 161
Study 22691828 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachosil® (hemostatic-sealant drug) used as a reinforcement of the suture line in sleeve gastrectomy
Number of subjects: 30
Study 22691828 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Tachosil®)
Number of subjects: 30
Study 22691828 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachosil®
Number of subjects: 30
Study 19874077 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Astrand bicycle test
Number of subjects: 64
Study 19874077 — intervention group
Group type: COMPARATOR
Intervention: Astrand bicycle test
Number of subjects: 64
Study 17335391 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal eye field and visual cortex activity during successful goal-directed saccades
Number of subjects: 0
Study 17335391 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural activity following saccadic movement
Number of subjects: 0
Study 17335391 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-related activity in the frontal eye fields
Number of subjects: 0
Study 15371022 — intervention group
Group type: EXPERIMENTAL
Intervention: African American client portrayal
Number of subjects: 0
Study 15371022 — intervention group
Group type: EXPERIMENTAL
Intervention: European American client portrayal
Number of subjects: 0
Study 15371022 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian American client portrayal
Number of subjects: 0
Study 11479066 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-month intervention program
Number of subjects: 76
Study 11479066 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 15 months
Number of subjects: 76
Study 11479066 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up study
Number of subjects: 76
Study 11479066 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 76
Study 11479066 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to other mental health agencies
Number of subjects: 76
Study 11479066 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuity of outpatient care
Number of subjects: 76
Study 9153724 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 260
Study 9153724 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 260
Study 7954550 — intervention group
Group type: EXPERIMENTAL
Intervention: Xipamide, 20 mg/day
Number of subjects: 139
Study 7954550 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone, 200 mg/day combined with furosemide, 40 mg on alternate days
Number of subjects: 139
Study 7954550 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide, 10-40 mg/day combined with spironolactone, 50-400 mg/day
Number of subjects: 139